Valuation: Renalytix Ai PLC

Market Cap 13.34M 11.69M 10.8M 9.94M 18.78M 1.29B 19.07M 129M 50.57M 629M 50.08M 48.98M 2.17B P/E 2024
-0.45x
P/E 2025 -1.34x
Enterprise Value 17.94M 15.72M 14.53M 13.36M 25.26M 1.73B 25.65M 173M 68.02M 846M 67.35M 65.88M 2.91B EV / Sales 2024
11,059,330x
EV / Sales 2025 12,499,418x
Free-Float
73.31%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 58 15/03/2018
President 65 30/04/2024
Director of Finance/CFO 68 28/05/2024
Director TitleAgeSince
Chairman 62 05/11/2024
Director/Board Member 58 15/03/2018
Chairman 74 -
Change 5-day change 1-year change 3-year change Capi.($)
+11.48%+33.33% - - 16.17M
-2.47%-1.90%+15.75%-25.65% 17.27B
+1.64%-5.48%+0.79%+91.39% 1.57B
-4.60%-9.25%-34.85%-80.19% 1.19B
+1.29%-4.72%-37.01%+15.19% 999M
-0.64%+2.18%-28.81%-52.65% 644M
-1.79%-5.76%-41.68%-57.20% 532M
+0.66%-3.89%+46.69%-53.85% 445M
0.00%+0.64%-54.33%-58.66% 382M
+1.09%+7.51%-18.78%-22.74% 364M
Average +0.67%-1.79%-16.91%-27.15% 2.6B
Weighted average by Cap. -1.91%-0.35%+6.30%-21.32%

Financials

2024 2025
Net sales 2.29 2.01 1.85 1.71 3.22 220.74 3.27 22.14 8.68 107.98 8.59 8.41 371.83 3 2.63 2.43 2.24 4.22 289.3 4.29 29.01 11.38 141.52 11.26 11.02 487.33
Net income -33.46M -29.32M -27.1M -24.93M -47.11M -3.23B -47.84M -324M -127M -1.58B -126M -123M -5.43B -20.4M -17.88M -16.52M -15.2M -28.73M -1.97B -29.17M -197M -77.36M -962M -76.6M -74.93M -3.31B
Net Debt 3.86M 3.38M 3.12M 2.87M 5.43M 372M 5.51M 37.28M 14.62M 182M 14.48M 14.16M 626M 4.6M 4.03M 3.73M 3.43M 6.48M 444M 6.58M 44.48M 17.44M 217M 17.27M 16.9M 747M
Logo Renalytix Ai PLC
Renalytix plc is a United Kingdom-based company, which is engaged in the development of artificial intelligence-enabled clinical diagnostic solutions for kidney disease. The Company is engaged in a field of bioprognosis for kidney health. The Company has engineered a solution that enables early-stage chronic kidney disease progression risk assessment. KidneyIntelX, is a vitro diagnostic platform, employs a proprietary algorithm that combines diverse data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record or EHR, systems, to generate a patient risk score. KidneyIntelX has been granted designation by the United States Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.
Employees
-